Will anti-amyloid therapies work for Alzheimer's disease?

The Lancet

Volumn 372, Issue 9634, 2008, Pages 180-182

  St George Hyslop, Peter H ^a,b   Morris, John C ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42];

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; SURVIVAL RATE; VACCINATION;

EID: 47349114997     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61047-8     Document Type: Note

References (13)

1. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
2. Schenk D., Barbour R., Dunn W., et al. Immunization with Aβ attenuates Alzheimer's Disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
3. Janus C., Pearson J., McLaurin J., et al. Aβ immunization reduces behavioural impairment and dense-cored plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
4. Glenner G., and Wong C. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120 (1984) 885-890
5. Walsh D., and Selkoe D. Aβ oligomers-a decade of discovery. J Neurochem 101 (2007) 1172-1184
6. -42 deposition precedes other changes in PS-1 Alzheimer's disease. Lancet 352 (1998) 1117-1118
7. Price J., and Morris J. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45 (1999) 358-368
8. Rogaeva E., Kawarai T., and George-Hyslop P. Genetic complexity of Alzheimer's disease: successes and challenges. J Alzheimers Dis 9 suppl 3 (2006) 381-387
9. Schupf N., and Sergievsky G. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 180 (2002) 405-410
10. Lewis J., Dickson D., Lin W., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
11. Roberson E., Scearce-Levie K., Palop J., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007) 750-754
12. Santacruz K., Lewis J., Spires T., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
13. Aktas O., Ullrich O., Infante-Duarte C., Nitsch R., and Zipp F. Neuronal damage in brain inflammation. Arch Neurol 64 (2007) 185-189